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Abstract
With the purpose to prevent the dissemination and consequent metastasis of cancer cells at the
time of operation we gave 10 mg of Mitomycin C per day for four consecutive days prior to surgical
operation of gastric cancer (total of 322 patients), and this so-called adjuvant chemotherapy proved
to be effective on the cases with serosal involvement and infiltrating type of cancer, irrespective
of histological types. It also gave five-year survival rate of 35 per cent. However, to lymph nodes
already metastasized, the adjuvant chemotherapy proved to be not effective.
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Because of lack of subjective symptoms the treatment of gastric cancer may
often start in its late stage and owing to the characteristics of rapid, dissemi-
nating metastases of the cancer cells to lymph nodes and subserosal tissue, the
prognosis after the operation is much less favorable than that of cancers of other
organs, even though the operation itself is radical and extensive. Actually most
of the patients die from remote metastases than from local recurrence. For this
reason chemotherapy combined with surgical operation has been increasingly
employed to prevent the recurrence. In view of this we used Mitomycin C
prior to the surgical operation with the purpose to check the dissemination of
cancer cells freed at operation. The results of this study are briefly presented in
the following.
MATERIALS AND METHODS
One of the features of the operation for gastric cancer performed in our
clinic is to eradicate all the regional lymph nodes lying above the transverse
colon as well as those communicating with these nodes. This includes not
only the removal of greater omentum but of the anterior leaf of mesocolon,
pancreatic capsule, lesser omentum and their adjacent tissues located along
hepatic artery and bile duct.
As the antitumor agent, Mitomycin-C. was used in the dose of 10 mg per
day for four consecutive days prior to the operation. The cases in which the
administration of the agent had to be suspended because of its side-effects were
excluded from this statistical study.
FOLLOW-UP STUDY OF PROGNOSIS
During January 1958 to July 1962, 322 patients were submitted to either
radical or palliative operation for gastric cancer. These cases were divided at
ranbom into two gruops; the chemotherapy and the non-chemotherapy groups.
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The patients surviving more than five years were subjected to detailed analysis
of the severity of cancer; serosal involvement, lymph-node metastasis, etc., by
macroscopic and microscopic examinations.
Overall results are illustrated in Fig. 1. In those patients to whom radical
operation with chemotherapy was performed, three-year survival rate proved
to be 43 per cent (48 out of 111 cases) and five-year survival, 35 per cent (17 out
of 47). This result is noteworthy in contrast to the result of patients receiving
radical operation without chemotherapy in that 40 per cent of the patients (23
out of 57) survived three years and 26 per cent (7 out of 27) five years post-
operatively. In those patients undergoing palliative operation combined with
prior chemotherapy, only one of 62 patients survived three years after the
operation, and none survived for five years. On the contrary, the excellent
results were obtained in the patients undergoing palliative operation without
chemotherapy; 12 per cent (5 out of 43) survived three years and 4 per cent (1
out of 26) five years.
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Fig. 1 Survival curve of surgical adjuvant chemotherapy for gastrie cancer
a: Radical operation + chemotherapy, b: Radical operation, c: Palliative
resection, d: Palliative resection + chemotherapy
Of the patients in Stage I on which no macroscopic metastases nor infiltra-
tion was observed in liver, peritoneum, lymph nodes or serosal membrane,
there was no death from recurrent cancer within five years after the operation
in both the chemotherapy and non-chemotherapy groups, Of the patients in
Stage II, showing no paritoneal dissemination nor liver metastasis by having
slight metastasis in the primary and secondary lymph nodes and serosal infiltra-
tion, the five-year survival was better for the chemotherapy group than for the
non-chemotherapy one; 27 per cent (3 out of 11) and 14 per cent (lout of 7),
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respectively. In Stage III with severe serosal invasion and metastases to the
third group of lymph nodes, 38 per cent (13 out of 34) of patients with chemo-
therapy survived five years after the operation, but the five-year survival rate
declined to 13 per cent (2 out of 16) in the non-chemotherapy group.
In the cases without serosal involvement, the five-year survival was 42 per
cent (5 out of 12) in the chemotherapy group and this is slightly worse than in
the non-chemotherapy group of 60 per cent. In the chemotherapy group the
five-year survival was 47 per cent (6 out of 13) in the cases with a slight serosal
involvement, and 29 per cent (6 out of 21) in the cases with severe serosal
invasion. In contrast, in the non-chemotherapy group with slight serosal in-
volvement none survived five years while those with severe serosal involvement
11 per cent did survive five years.
In those without lymph-node metastasis, long-term prognosis was a little
better in the non-chemotherapy group than in the chemotherapy group. On the
other hand, chemotherapy contributes significantly to the five-year survival in
those with metastasis to the primary and tertiary nodes.
On the localized type of Borrmann, 10 out of 20 cases (50%) with chemo-
therapy survived more than five years while 4 out of 10 cases without chemo-
therapy. In the infiltrating type of Borrmann, the five-year survival was 24
per cent (7 out of 27) in the chemotherapy group, and 18 per cent (3 out of 17)
in the non-chemotherapy. Chemotherapy seems to have improved the survival
rate in both types, especially in the latter.
The five-year survival was 38 per cent of those with adenocarcinoma and
29 per cent of these with carcinoma solidum simplex in the chemotherapy
group, which is significantly better than that in the non-chemotherapy group of
19 per cent and of 14 per cent respectively.
DISCUSSION
The objective of the chemotherapy adjuvant to surgery is to improve the
therapeutic effects in combination with radical operation. MARTIN4 emphasized
that for human cancer the anticancer agent is only significant as an adjuvant
therapy and stated that cancer cells freed during surgical procedure are the most
suitable target of chemotherapy. The clinical evaluation of chemotherapeutic
effects is usually difficult. MOORE6 suggested that a long-term follow-up of five
and ten years must be obtained before any conclusive statement can be made.
The effect of chemotherapy must be evaluated not on the basis of transient
improvement or symptomatic remission, but on the basis of follow-up study.
It must be postulated that the follow-up should include patients treated during
an identical period with and without chemotherapy.
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Under such conditions, MOORE5 concluded that chemotherapy did not
produce a significant difference in the four-year survival rate. In our series,
chemotherapy as an adjuvant to radical surgery indicated better prognosis than
when an anticancer drug was not used. The present results suggest that the
anticancer drug inhibits free cancer cells to disseminate and metastasize, when
the main tumor tissues are removed by radical surgery.
In those patients undergoing palliative surgery, better prognosis is obtained
by surgical operation alone than by operation with chemotherapy. This result
is in agreement with that of OHARA6 who suggested that chemotherapy may be
insignificant to surgically inoperable cancer of the stomach. This may be due
to the adverse effect of anticancer agent but further study seems to be neces-
sary. In relation to the advancement of the grade of cancer, adjuvant chemo-
therapy did not produce any better results in those patients in Stage I than
radical surgery alone. For patients in more advanced Stages II and III, chemo-
therapy significantly improved the long-term prognosis. This agreed with the
experimental observation7 using MH-134 ascitic hepatoma with Nitromin that
surgical adjuvant chemotherapy produced more significant effect on advanced
cancer.
When the cancer had invaded the serosa, prognosis of the patients without
chemotherapy is much worse than those with chemotherapy. The risk of
polluting the operative field by cancer cells abraded during the surgical procedure
had been suggested1.2. 8 • Chemotherapy may prevent the dissemination of ex-
foliated cancer cells.
Cases with lymph-node metastasis are not influenced by chemotherapy.
This may be due to adequate lymph-node extirpation performed during operation
on the cases which was reported in this study, while the effect of an anticancer
agent on metastasized lymph nodes, especially on microsolitary metastatic focus
was previously reported by the present author3• It is generally believed that an
antitumor agent can be effective on such a small metastatic focus but not on
extended metastases. It is assumed that chemotherapy without surgical removal
of lymph nodes shows no clinical result.
Chemotherapy appears to be more effective to the cancer of infiltrating
type than to localized type. This may be explained similarly to its effect on cases
with serosal involvement.
In summary, adjuvant chemotherapy appears to be effective to prevent the
contamination of the operative field by exfoliating cancer cells freed during
surgery. Some limitation of anticancer therapy is noted to lymph nodes already
metastasized.
Adjuvant chemotherapy obtained better prognosis irrespective of the histo-
logical type of the cancer. So far chemotherapy appears to improve the prognosis
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when used in combination with radical surgery for cancer, and further study is
necessary to evaluate the methods of administration of the anticancer agent.
CONCLUSION
With the purpose to prevent the dissemination and consequent metastasis of
cancer cells at the time of operation we gave 10 mg of Mitomycin C per day for
four consecutive days prior to surgical operation of gastric cancer (total of 322
patients), and this so-called adjuvant chemotherapy proved to be effective on the
cases with serosal involvement and infiltrating type of cancer, irrespective of
histological types. It also gave five-year survival rate of 35 per cent. However,
to lymph nodes already metastasized, the adjuvant chemotherapy proved to be
not effective.
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